These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 18398462)
1. Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. Rebetz J; Tian D; Persson A; Widegren B; Salford LG; Englund E; Gisselsson D; Fan X PLoS One; 2008 Apr; 3(4):e1936. PubMed ID: 18398462 [TBL] [Abstract][Full Text] [Related]
2. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Ogden AT; Waziri AE; Lochhead RA; Fusco D; Lopez K; Ellis JA; Kang J; Assanah M; McKhann GM; Sisti MB; McCormick PC; Canoll P; Bruce JN Neurosurgery; 2008 Feb; 62(2):505-14; discussion 514-5. PubMed ID: 18382330 [TBL] [Abstract][Full Text] [Related]
3. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Beier D; Wischhusen J; Dietmaier W; Hau P; Proescholdt M; Brawanski A; Bogdahn U; Beier CP Brain Pathol; 2008 Jul; 18(3):370-7. PubMed ID: 18371181 [TBL] [Abstract][Full Text] [Related]
4. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Prestegarden L; Svendsen A; Wang J; Sleire L; Skaftnesmo KO; Bjerkvig R; Yan T; Askland L; Persson A; Sakariassen PØ; Enger PØ Cancer Res; 2010 Jun; 70(11):4274-9. PubMed ID: 20460538 [TBL] [Abstract][Full Text] [Related]
5. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713 [TBL] [Abstract][Full Text] [Related]
6. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dahlrot RH Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629 [TBL] [Abstract][Full Text] [Related]
7. [Correlative study of distribution of brain tumor stem cell with micro-vascular system]. Li MW; Niu CS Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050 [TBL] [Abstract][Full Text] [Related]
8. Isolation and partial characterization of a new human glioblastoma cell line. Brehar FM; Bleotu C; Stefan LM; Buzgariu W; Chivu M; Utoiu E; Matei L; Ciurea AV; Tascu A Chirurgia (Bucur); 2009; 104(4):453-61. PubMed ID: 19886054 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis. Han M; Guo L; Zhang Y; Huang B; Chen A; Chen W; Liu X; Sun S; Wang K; Liu A; Li X Mol Neurobiol; 2016 Jan; 53(1):720-727. PubMed ID: 25589004 [TBL] [Abstract][Full Text] [Related]
10. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth. Di K; Linskey ME; Bota DA Oncogene; 2013 Oct; 32(42):5038-47. PubMed ID: 23178488 [TBL] [Abstract][Full Text] [Related]
12. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas. Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792 [TBL] [Abstract][Full Text] [Related]
13. In vitro neurosphere formation correlates with poor survival in glioma. C Jayakrishnan P; H Venkat E; M Ramachandran G; K Kesavapisharady K; N Nair S; Bharathan B; Radhakrishnan N; Gopala S IUBMB Life; 2019 Feb; 71(2):244-253. PubMed ID: 30393962 [TBL] [Abstract][Full Text] [Related]
14. In vitro identification and functional characterization of glial precursor cells in human gliomas. Colin C; Baeza N; Tong S; Bouvier C; Quilichini B; Durbec P; Figarella-Branger D Neuropathol Appl Neurobiol; 2006 Apr; 32(2):189-202. PubMed ID: 16599947 [TBL] [Abstract][Full Text] [Related]
15. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Wu A; Oh S; Wiesner SM; Ericson K; Chen L; Hall WA; Champoux PE; Low WC; Ohlfest JR Stem Cells Dev; 2008 Feb; 17(1):173-84. PubMed ID: 18271701 [TBL] [Abstract][Full Text] [Related]
16. Clinical value of CD133 and nestin in patients with glioma: a population-based study. Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750 [TBL] [Abstract][Full Text] [Related]
17. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy. Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844 [TBL] [Abstract][Full Text] [Related]
18. What is the clinical value of cancer stem cell markers in gliomas? Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423 [TBL] [Abstract][Full Text] [Related]
19. Study on the proliferation and drug-resistance of human brain tumor stem-like cells. Qin K; Jiang X; Zou Y; Wang J; Qin L; Zeng Y Cell Mol Neurobiol; 2010 Aug; 30(6):955-60. PubMed ID: 20526804 [TBL] [Abstract][Full Text] [Related]
20. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. He J; Liu Y; Zhu T; Zhu J; Dimeco F; Vescovi AL; Heth JA; Muraszko KM; Fan X; Lubman DM Mol Cell Proteomics; 2012 Jun; 11(6):M111.010744. PubMed ID: 22203689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]